Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21042943 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL2606791 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL21612902 | 0.98 | ALDH1A1 (0.51) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL11977462 | 0.88 | LMNA (0.46) | ALDH1A1POLBLMNA | |
| SCHEMBL15188004 | 0.88 | LMNA (0.46) | ALDH1A1POLBLMNA | |
| SCHEMBL12102740 | 0.88 | LMNA (0.46) | ALDH1A1POLBLMNA | |
| SCHEMBL11923163 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2AHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL4971987 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KMT2AHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL8258796 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KMT2AHSD17B10SMN1; SMN2KDM4E | |
| SCHEMBL18501697 | 0.83 | ATM (0.34) | ALDH1A1KMT2AHSD17B10SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | ALDH1A1 842/4885KMT2A 4470/4885HSD17B10 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.